Teva Pharmaceutical Industries Ltd
F:TEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Teva Pharmaceutical Industries Ltd
F:TEV
|
IL |
|
Chandra Asri Petrochemical Tbk PT
IDX:TPIA
|
ID |
|
Evolution AB (publ)
STO:EVO
|
SE |
|
M
|
Magna International Inc
DUS:MGA
|
CA |
|
M
|
MarineMax Inc
F:MLW
|
US |
|
Stryker Corp
NYSE:SYK
|
US |
|
Cicor Technologies Ltd
SIX:CICN
|
CH |
|
F
|
Flowers Foods Inc
SWB:FWF
|
US |
|
G
|
Goldman Sachs Group Inc
BMV:GS
|
US |
|
G
|
Galactico Corporate Services Ltd
BSE:542802
|
IN |
|
C
|
Canada Goose Holdings Inc
NYSE:GOOS
|
CA |
|
MasTec Inc
NYSE:MTZ
|
US |
|
SK Innovation Co Ltd
KRX:096775
|
KR |
|
V
|
Verizon Communications Inc
XHAM:BAC
|
US |
|
S
|
SandRidge Energy Inc
SWB:SA2D
|
US |
|
S
|
Semirara Mining and Power Corp
XPHS:SCC
|
PH |
|
HeidelbergCement AG
XETRA:HEI
|
DE |
|
U
|
UPM-Kymmene Oyj
XMUN:RPL
|
FI |
|
Shell PLC
F:L3H
|
UK |
|
Siemens AG
OTC:SIEGY
|
DE |
|
RWE AG
MIL:1RWE
|
DE |
|
Kubota Corp
F:KUO1
|
JP |
|
T
|
Texas Instruments Inc
BMV:TXN
|
US |
|
A
|
Aluminum Corporation of China Ltd
SWB:AOC
|
CN |
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries is a global drug company best known for making generic medicines, which are lower-cost versions of branded drugs after patent protection ends. It also sells a smaller portfolio of branded specialty medicines, with a focus on treatments for the nervous system, breathing problems, and other chronic conditions. Its products are sold to pharmacies, hospitals, doctors, governments, and health systems around the world. Teva makes money mainly by selling finished medicines, either under its own name or through large-volume generic supply contracts. In generics, it competes on cost, manufacturing scale, and the ability to launch approved alternatives quickly when patents expire. In specialty drugs, it earns more from branded therapies that treat specific diseases and often require ongoing prescriptions. What makes Teva important in the drug industry is its role as a major supplier of affordable medicines. It sits between patent-based drug makers and the patients, insurers, and public health systems that need lower-priced alternatives. That mix of high-volume generics and selected branded treatments gives Teva a business model that depends on manufacturing strength, regulatory approvals, and broad distribution rather than a single blockbuster drug.
Teva Pharmaceutical Industries is a global drug company best known for making generic medicines, which are lower-cost versions of branded drugs after patent protection ends. It also sells a smaller portfolio of branded specialty medicines, with a focus on treatments for the nervous system, breathing problems, and other chronic conditions. Its products are sold to pharmacies, hospitals, doctors, governments, and health systems around the world.
Teva makes money mainly by selling finished medicines, either under its own name or through large-volume generic supply contracts. In generics, it competes on cost, manufacturing scale, and the ability to launch approved alternatives quickly when patents expire. In specialty drugs, it earns more from branded therapies that treat specific diseases and often require ongoing prescriptions.
What makes Teva important in the drug industry is its role as a major supplier of affordable medicines. It sits between patent-based drug makers and the patients, insurers, and public health systems that need lower-priced alternatives. That mix of high-volume generics and selected branded treatments gives Teva a business model that depends on manufacturing strength, regulatory approvals, and broad distribution rather than a single blockbuster drug.
Growth engines: Teva said AUSTEDO, AJOVY and UZEDY all had strong Q2 results, and management raised full-year revenue guidance for each of the three products.
Margins and cash: Revenue was stable despite the drag from generic REVLIMID, gross margin improved by 80 basis points, and free cash flow rose 31%.
Pipeline momentum: Management highlighted 8 major pipeline milestones this year, including olanzapine, ecopipane, DARI, celiac data and new TL1A indications.
Generics mixed: The generics business declined 15% year over year, but management said that excluding REVLIMID it was broadly stable and still capable of low single-digit long-term growth.
Balance sheet: Teva said Fitch upgraded it to investment grade and that net debt-to-EBITDA would have been 2.3x excluding the MLX deal, moving toward the 2x target by 2027.
Investor focus: Analysts pressed management on AUSTEDO payer dynamics ahead of 2027, celiac readout timing, biosimilars growth, and the impact of U.S. tariffs.